Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Gains from Investment Securities of $8.5 million for Q1 2026, up 573.09% year-over-year from $1.3 million in Q1 2025, and up 4259.79% on a QoQ basis from $194000.0 in Q4 2025.
Rhythm Pharmaceuticals (RYTM) has 11 years of Gains from Investment Securities data on file, last reported at $8.5 million in Q1 2026.
- Quarterly Gains from Investment Securities rose 573.09% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (up 744.66% YoY) and the FY2025 annual result came in at -$90000.0, down 186.03% from the prior year.
- Gains from Investment Securities grew to $8.5 million in Q1 2026 per RYTM's latest filing, from $194000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $8.5 million in Q1 2026 and bottomed at -$1.2 million in Q1 2024.
- The 5-year median for Gains from Investment Securities is $1.3 million (2023), against an average of $1.9 million.
- Peak annual rise in Gains from Investment Securities reached 78825.0% in 2024, while the deepest fall reached 385.89% in 2024.
- Tracing RYTM's Gains from Investment Securities over 5 years: stood at -$1000.0 in 2022, then soared by 500.0% to $4000.0 in 2023, then surged by 78825.0% to $3.2 million in 2024, then tumbled by 93.85% to $194000.0 in 2025, then jumped by 4259.79% to $8.5 million in 2026.
- Per Business Quant, the three latest RYTM Gains from Investment Securities figures stand at $8.5 million (Q1 2026), $194000.0 (Q4 2025), and $3.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Rhythm Pharmaceuticals | 6.00 Bn | 5.66 Bn | 52.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.46 Mn |
| Mar 31, 2026 | 8.46 Mn |
| Dec 31, 2025 | 194,000.00 |
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 3.13 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.13 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | -1.20 Mn |
| Mar 31, 2024 | -1.20 Mn |
| Dec 31, 2023 | 4,000.00 |
| Dec 31, 2023 | 4,000.00 |
| Sep 30, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 295,985.00 |
| Jun 30, 2023 | 295,985.00 |
| Mar 31, 2023 | 417,995.00 |
| Mar 31, 2023 | 417,995.00 |
| Dec 31, 2022 | -1,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | 1.37 Mn |
| Sep 30, 2022 | 1.37 Mn |
| Jun 30, 2022 | 909,140.00 |
| Jun 30, 2022 | 909,140.00 |
| Mar 31, 2022 | 6.66 Mn |
| Mar 31, 2022 | 6.66 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Sep 30, 2021 | 962,942.00 |
| Sep 30, 2021 | 962,942.00 |
| Jun 30, 2021 | 983,993.00 |
| Jun 30, 2021 | 983,993.00 |
| Mar 31, 2021 | 983,993.00 |
| Mar 31, 2021 | 983,993.00 |
| Sep 30, 2020 | 1.00 Mn |
| Sep 30, 2020 | 1.00 Mn |
| Jun 30, 2020 | 1.01 Mn |
| Jun 30, 2020 | 1.01 Mn |
| Mar 31, 2020 | 1.01 Mn |
| Mar 31, 2020 | 1.01 Mn |
| Dec 31, 2019 | 1.45 Mn |
| Dec 31, 2019 | 1.45 Mn |
| Dec 31, 2018 | 1.22 Mn |
| Dec 31, 2018 | 1.22 Mn |
| Dec 31, 2017 | 1.11 Mn |
| Dec 31, 2017 | 1.11 Mn |
| Dec 31, 2016 | 164,229.00 |
| Dec 31, 2016 | 164,229.00 |